Literature DB >> 30187723

Immunotherapy a New Hope for Cancer Treatment: A Review.

Fatemeh Nouri Rouzbahani, Mohammad Shirkhoda, Feridon Memari, Hassan Dana, Ghanbar Mahmoodi Chalbatani, Habibollah Mahmoodzadeh, Nasim Samarghandi, Elahe Gharagozlou, Mohammad Hosein Mohammadi Hadloo, Ali Reza Maleki, Ehsan Sadeghian, ElhamZainali Nia, Nedazainali Nia, Farimah Hadjilooei, Omid Rezaeian, Saeed Meghdadi, SeyedRohollah Miri, Fatameh Jafari, Elham Rayzan, Vahid Marmari.   

Abstract

Cancer is a major burden of disease worldwide with considerable impact on society. The tide of immunotherapy has finally changed after decades of disappointing results and has become a clinically validated treatment for many cancers. Immunotherapy takes many forms in cancer treatment, including the adoptive transfer of ex vivo activated T cells, oncolytic viruses, natural killer cells, cancer vaccines and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. Recently, cancer immunotherapy has received a high degree of attention, which mainly contains the treatments for programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), chimeric antigen receptors (CARs) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Here, this paper reviewed the current understandings of the main strategies in cancer immunotherapy (adoptive cellular immunotherapy, immune checkpoint blockade, oncolytic viruses and cancer vaccines) and discuss the progress in the synergistic design of immune-targeting combination therapies.

Entities:  

Keywords:  CAR-T cell therapy; CTLA4; Combination therapies; Immunotherapy; programmed death ligand 1 (PD-L1)

Mesh:

Substances:

Year:  2018        PMID: 30187723     DOI: 10.3923/pjbs.2018.135.150

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  11 in total

Review 1.  The significance of PAK4 in signaling and clinicopathology: A review.

Authors:  Xinbo Yu; Changwei Huang; Jiyuan Liu; Xinyu Shi; Xiaodong Li
Journal:  Open Life Sci       Date:  2022-06-20       Impact factor: 1.311

Review 2.  The Role of Photodynamic Therapy in Triggering Cell Death and Facilitating Antitumor Immunology.

Authors:  Liuchang Tan; Xiaoxiao Shen; Zhiqiang He; Yuangang Lu
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

Review 3.  Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progression.

Authors:  Shyam K Bandari; Kaushlendra Tripathi; Sunil Rangarajan; Ralph D Sanderson
Journal:  Cancer Lett       Date:  2020-08-26       Impact factor: 8.679

4.  Long non-coding RNA TRPM2 antisense RNA as a potential therapeutic target promotes tumorigenesis and metastasis in esophageal cancer.

Authors:  Wei Wang; Yukai Dai; Xin Yang; Xinming Xiong
Journal:  Bioengineered       Date:  2022-02       Impact factor: 6.832

5.  Inducing multiple antibodies to treat squamous cell esophageal carcinoma.

Authors:  Isamu Hoshino; Yoshihiro Nabeya; Nobuhiro Takiguchi; Hisashi Gunji; Fumitaka Ishige; Yosuke Iwatate; Akiko Kuwajima; Fumiaki Shiratori; Rei Okada; Hideaki Shimada
Journal:  BMC Cancer       Date:  2020-10-17       Impact factor: 4.430

Review 6.  The Influence of Analgesic Modalities on Postoperative Cancer Recurrence.

Authors:  Amber N Edinoff; Olivia C Derise; Aaron J Sheppard; Sumitra Miriyala; Celina G Virgen; Aaron J Kaye; Mohammad Niakan; Elyse M Cornett; Alan D Kaye
Journal:  Anesth Pain Med       Date:  2022-02-22

7.  The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study.

Authors:  Valentina Masciale; Federico Banchelli; Giulia Grisendi; Roberto D'Amico; Antonino Maiorana; Alessandro Stefani; Uliano Morandi; Franco Stella; Massimo Dominici; Beatrice Aramini
Journal:  Stem Cells Transl Med       Date:  2022-03-31       Impact factor: 6.940

Review 8.  Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.

Authors:  Yifan Ren; Jialong Song; Xinyi Li; Na Luo
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

9.  Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.

Authors:  Yezi Chen; Xiaoqin Luo; Yun Liu; Yunlei Zou; Shiqi Yang; Chaoqi Liu; Yun Zhao
Journal:  Int J Nanomedicine       Date:  2022-09-07

10.  SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.

Authors:  Wei Yang; Bing Han; Yecheng Chen; Feng Geng
Journal:  Aging (Albany NY)       Date:  2022-08-13       Impact factor: 5.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.